PBS 119

Drug Profile

PBS 119

Alternative Names: PBS-119

Latest Information Update: 24 Feb 2010

Price : $50

At a glance

  • Originator Phoenix Biosciences
  • Class Antiretrovirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 24 Feb 2010 No development reported - Phase-I for HIV infections in USA (unspecified route)
  • 01 Jul 2004 Pilot trials in HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top